Publications of Sascha Young Kupke
All genres
Journal Article (17)
2024
Journal Article
108, pp. 1 - 15 (2024)
Production of antiviral “OP7 chimera” defective interfering particles free of infectious virus. Applied Microbiology and Biotechnology
Journal Article
27 (4), 109421 (2024)
Mathematical model calibrated to in vitro data predicts mechanisms of antiviral action of the influenza defective interfering particle “OP7”. iScience 2023
Journal Article
13, 20936 (2023)
Generation of “OP7 chimera” defective interfering influenza A particle preparations free of infectious virus that show antiviral efficacy in mice. Scientific Reports
Journal Article
107, pp. 5947 - 5961 (2023)
Production of retroviral vectors in continuous high cell density culture. Applied Microbiology and Biotechnology
Journal Article
15 (9), 1872 (2023)
Broad-Spectrum Antiviral Activity of Influenza A Defective Interfering Particles against Respiratory Syncytial, Yellow Fever, and Zika Virus Replication In Vitro. Viruses 2022
Journal Article
259, 104544 (2022)
Absolute quantification of viral proteins during single-round replication of MDCK suspension cells. Journal of Proteomics 2021
Journal Article
19 (1), 91 (2021)
Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles. BMC Biology
Journal Article
105, pp. 7251 - 7264 (2021)
Cell culture–based production of defective interfering influenza A virus particles in perfusion mode using an alternating tangential flow filtration system. Applied Microbiology and Biotechnology
Journal Article
105 (1), pp. 129 - 146 (2021)
OP7, a novel influenza A virus defective interfering particle: production, purification, and animal experiments demonstrating antiviral potential. Applied Microbiology and Biotechnology
Journal Article
95 (24), e01174-21 (2021)
Semi-continuous propagation of influenza A virus and its defective interfering particles: analyzing the dynamic competition to select candidates for antiviral therapy. Journal of Virology
Journal Article
10 (7), 1756 (2021)
Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity. Cells
Journal Article
17, e1009357 (2021)
Multiscale model of defective interfering particle replication for influenza A virus infection in animal cell culture. PLoS Computational Biology 2020
Journal Article
12 (1), 71 (2020)
Single-Cell Analysis Uncovers a Vast Diversity in Intracellular Viral Defective Interfering RNA Content Affecting the Large Cell-to-Cell Heterogeneity in Influenza A Virus Replication. Viruses 2019
Journal Article
93 (4), 01786-18 (2019)
A Novel Type of Influenza A Virus-Derived Defective Interfering Particle with Nucleotide Substitutions in Its Genome. Journal of Virology
Journal Article
15 (2), e1006819 (2019)
Multiscale modeling of influenza A virus replication in cell cultures predicts infection dynamics for highly different infection conditions. PLoS Computational Biology 2016
Journal Article
100 (16), pp. 7181 - 7192 (2016)
Influenza virus intracellular replication dynamics, release kinetics, and particle morphology during propagation in MDCK cells. Applied Microbiology and Biotechnology 2015
Journal Article
6, 8938 (2015)
Single-cell analysis and stochastic modelling unveil large cell-to-cell variability in influenza A virus infection. Nature Communications Conference Paper (1)
2018
Conference Paper
51 (19), pp. 32 - 33 (2018)
A multiscale model of influenza A virus replication covering highly different infection conditions in cell cultures. IFAC-PapersOnLine Meeting Abstract (2)
2019
Meeting Abstract
Continuous mode of production for two classes of defective interfering influenza A virus particles as antiviral candidates. In Integrated Continuous Biomanufacturing IV, 76. Biomanufact IV, Ocean Edge Resort Brewster (Cape Cod), Massachusetts, USA , October 06, 2019 - October 10, 2019. (2019)
2018
Meeting Abstract
Single-cell analysis uncovers a novel influenza A virus-derived defective interfering particle for antiviral therapy. In Vaccine Technology VII, 133. Vaccine Technology VII, Mont Tremblant, Canada, June 17, 2018 - June 22, 2018. (2018)